Current role of activated protein C therapy for severe sepsis and septic shock

Current Infectious Disease Reports

Volumn 10, Issue 5, 2008, Pages 368-376

  Barie, Philip S ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; DOPAMINE; DROTRECOGIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

APACHE; ARTIFICIAL VENTILATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PROTEIN C DEFICIENCY; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

EID: 60749131919     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0060-5     Document Type: Review

References (36)

1. Bernard GR, Vincent JL, Laterre PF, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
2. Abraham E, Laterre PF, Garg R, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353: 1332-1341. 353:1332-1341.
3. Nadel S, Goldstein B, Williams MD, et al.: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007, 369:836-843.
4. Payen D, Sablotzki A, Barie PS, et al.: International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort. Surgery 2007, 141:548-561.
5. Barie PS, Williams MD, McCollam JS, et al.: PROWESS Surgical Evaluation Committee: Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004, 188:212-220.
6. Rowan KM, Welch CA, North E, Harrison DA: Drotrecogin alfa (activated): real-life use and outcomes for the UK. Crit Care 2008, 12:R58 (Epub ahead of print).
7. Vincent J-L, Laterre PF, Decruyenaere J, et al.: A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units: An observational study. Ann Clin Belg 2008, 63:25-30.
8. Wheeler A, Steingrub J, Schmidt GA, et al.: A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. Crit Care Med 2008, 36:14-23.
9. Laterre PF, Nelson DR, Macias W, et al.: International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety. J Crit Care 2007, 22:142-152.
10. Barie PS: An opinion too far - the campaign against the Surviving Sepsis Campaign. Surg Infect 2006, 7:485-488.
11. Dellinger RP, Levy MM, Carlet JM, et al.: International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36: 296-327. (Published erratum appears in Crit Care Med 2008, 36:1394-1936.)
12. Vincent JL, Bernard GR, Beale R, et al.: Drotrecogin alfa (activated) treatment in severe sepsis from the global openlabel trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005, 33:2266-2277.
13. Costa V, Brophy JM: Drotrecogin alfa (actAvated) in severe sepsis: a systematic review and new cost-effectiveness analysis. BMC Anesthesiol 2007, 7:5.
14. Levi M, Levy M, Williams MD, et al.: Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007, 176:483-490.
15. Barton P, Kalil AC, Nadel S, et al.: Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 2004, 113:7-17.
16. Goldstein B, Giroir B, Randolph A: International peidatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005, 6:2-8.
17. Martí-Carvajal A, Salanti G, Cardona AF: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2007, 3:CD004388.
18. Martí-Carvajal A, Salanti G, Cardona AF: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2008, 1:CD004388.
19. Bernard GR, Ely EW, Wright TJ, et al.: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001, 29:2051-2059.
20. Lundh A, Gøtzsche PC: Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol 2008, 8:22.
21. Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL: Spontaneous intracerebral hemorrhage in critically ill patients: Incidence over six years and associated factors. Intensive Care Med 1999, 25:63-67.
22. Warren BL, Eid A, Singer P, et al.: For the KyberSept Trial Study Group: high-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 2001, 286:1869-1878.
23. Abraham E, Reinhart K, Opal S, et al.: For the OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. A randomized controlled trial. JAMA 2003, 290: 238-247.
24. Laterre PF, Abraham E, Janes J, et al.: ADDRESS (ADministration of Drotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation. Crit Care Med 2007, 35:1457-1463.
25. Rowan KM, Welch CA, North E, Harrison DA: Drotrecogin alfa (activated): real-life use and outcomes for the UK. Crit Care 2008, 12:R58 (Epub ahead of print).
26. Vincent J-L, Laterre PF, Decruyenaere J, et al.: A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units - an observational study. Acta Clin Belg 2008, 63: 25-30.
27. Wheeler A, Steingrub J, Schmidt GA, et al.: A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. Crit Care Med 2008, 36:14-23.
28. Payen D, Sablotzki A, Barie PS, et al.: International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort. Surgery 2007, 141:548-561.
29. Friedrich JO: Drotrecogin alfa (activated) in severe sepsis. [comment]. N Engl J Med 2006, 354:94-96.
30. Opal SM: Can we RESOLVE the treatment of sepsis? [comment]. Lancet 2007, 369:803-804.
31. Gardlund B: Activated protein C (Xigris) treAtment in sepsis: a drug in trouble. Acta Anaesthesiol Scand 2006, 50:907-910.
32. US Food and Drug Administration: Xigris Face-to-Face Meeting, March 14, 2007. Investigational New Drug (IND) 5919, Amendment 460.
33. John J, Awab A, Norman D, et al.: Activated protein C improves survival in severe sepsis patients with elevated troponin. Intensive Care Med 2007, 33:2122-2128.
34. ShorrAAF, Nelson DR, Wyncoll DL, et al.: Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). Crit Care 2008, 12:R45 (Epub ahead of print).
35. Macias WL, Nelson DR: Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004, 32(Suppl):S223-S228.
36. Vangerow B, Shorr AF, Wyncoll D, et al.: The protein C pathway: implications for the design of the RESPOND study. Crit Care 2007, 11(Suppl5): S4.